Liminatus Pharma prices $4.0M public offering of common stock and warrants

Liminatus Pharma, Inc.

Offering of 13.8M shares/pre-funded warrants and warrants for up to 20.7M shares at combined $0.29 per unit.
Gross proceeds ~$4.0M; net proceeds ~$3.46M after placement agent fees and expenses.
Warrants exercisable immediately at $0.29 per share, expire 5 years from issuance.
Placement agent Maxim Group LLC receives 8% cash fee, $100K expense reimbursement, and 690,650 warrant shares at $0.319.
Directors and officers subject to 180-day lock-up; company restricted from certain equity issuances for 180 days.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Liminatus Pharma, Inc. entered into Purchase Agreement with certain purchasers party thereto (effective 2026-02-17).

Action: entry
Agreement: equity purchase
Counterparty: certain purchasers party thereto
Effective: 2026-02-17

Exact text from the filing

the Company entered into a securities purchase agreement (the "Purchase Agreement") with certain purchasers party thereto.

View on SEC.gov

303 material agreements filed in the last 30 days. Browse all material agreements →

Liminatus Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-017134

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.